LARGE1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Although a recent study demonstrates that fukutin is required for the ability of LARGE to hyperglycosylate αDG [24], this strategy is already regarded as a promising therapeutic approach for preventing/slowing progression of a broad range of dystroglycanopathies regardless of the causative gene defects.